{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013608","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.106222+00:00","generated_at":"2026-05-15T08:24:59.258203+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lantern Pharma FY2025 net loss narrows to $17.1M; cash runway into mid-2026; pipeline advances","bullets":["Cash and marketable securities $10.1M as of Dec 31, 2025, down from $24.0M; expects funding needs by late Jul–mid Sep 2026.","Full-year net loss $17.1M ($1.57/share) vs $20.8M ($1.93/share) in 2024; R&D expenses down 29% to $11.5M.","LP-300 HARMONIC trial: FDA Type C meeting scheduled mid-May 2026 to discuss protocol amendments focusing on EGFR exon 21 L858R patients.","LP-184 Phase 1a complete: 48% clinical benefit rate; Phase 1b/2 trials planned in TNBC, NSCLC with STK11/KEAP1 mutations.","withZeta.ai beta testing with 25+ biotech firms; company denies false report of CEO resignation, confirms Panna Sharma remains CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013608","json":"https://secwatch.observer/filing/0001493152-26-013608.json","markdown":"https://secwatch.observer/filing/0001493152-26-013608.md","text":"https://secwatch.observer/filing/0001493152-26-013608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226013608/0001493152-26-013608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226013608/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:24:59.258203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e75388d884ed386c293b981b102d15667e929aa3","claim":"Lantern Pharma Inc. reported financial results for the fiscal year and fourth quarter ended December 31, 2025.","evidence_excerpt":"On March 30, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226013608/0001493152-26-013608-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year and fourth quarter ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}